Daiichi Sankyo Signs an Outsourcing Agreement with AstraZeneca for COVID-19 Vaccine in Japan
Daiichi Sankyo and AstraZeneca’s Enhertu Receive the US FDA’s Approval for Previously Treated HER2-Positive Advanced Gastric Cancer
Shots:
- Daiichi Sankyo signs an outsourcing Agreement to Manufacture AstraZeneca COVID-19 Vaccine AZD1222 in Japan
- Following the AstraZeneca’s agreement with the Japanese government to manufacture and supply COVID-19 vaccine, Daiichi Sankyo will use undiluted solutions to manufacture COVID-19 vaccines in the Japan including vial filling and packaging
- Additionally, Daiichi Sankyo will continue to work to advance ongoing research and development of a Nafamostat inhalation formulation (DS2319) as well as an mRNA vaccine (DS-5670) and also ensures the supply of the AstraZeneca COVID-19 vaccine in Japan
Click here to read full press release/ article | Ref: Daichii Sankyo | Image: Daichii Sankyo